Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
Add more filters










Database
Language
Publication year range
1.
Transfusion ; 46(2): 193-8, 2006 Feb.
Article in English | MEDLINE | ID: mdl-16441594

ABSTRACT

BACKGROUND: High-dose therapy with autologous peripheral blood progenitor cell support is widely utilized but requires successful CD34+ cell mobilization and collection. Chemotherapy plus growth factors appear to mobilize more CD34+ cells than growth factors alone. Because alterations in expression of adhesion molecules are important in the trafficking of hematopoietic progenitors, the possibility was explored that the mechanism of this superior mobilization may be greater down regulation of adhesion molecules. STUDY DESIGN AND METHODS: The expression of eight adhesion molecules (CD11a, b, and c; 15s; 49d and e; 54; and 62L) on the collected CD34+ cells from 15 patients undergoing mobilization with chemotherapy plus granulocyte-colony-stimulating factor (G-CSF) was compared with those of 14 concomitant patients receiving G-CSF alone. RESULTS: Patients receiving chemotherapy plus G-CSF mobilized more CD34+ cells and did not differ in prior chemotherapy or radiation. There were no significant differences in the percentage of CD34+ cells expressing any of the adhesion molecules examined between the two groups. The chemotherapy plus G-CSF-mobilized cells consistently showed higher expression intensity, and this showed significance or a strong trend for CD11a and c, CD15s, and CD54. Despite these higher expression levels, there were no differences in engraftment kinetics. CONCLUSIONS: CD34+ cells mobilized by chemotherapy plus growth factors appear to have higher intensities of expression of several adhesion molecules. The significance of this observation will require further study.


Subject(s)
Antigens, CD34/metabolism , Antineoplastic Agents/administration & dosage , Cell Adhesion Molecules/metabolism , Granulocyte Colony-Stimulating Factor/administration & dosage , Hematopoietic Stem Cell Mobilization/methods , Stem Cells/metabolism , Adult , Aged , Breast Neoplasms/therapy , Female , Hematopoietic Stem Cell Transplantation , Hodgkin Disease/therapy , Humans , Lymphoma, Non-Hodgkin/therapy , Male , Middle Aged , Multiple Myeloma/therapy , Sarcoma/therapy , Stem Cells/cytology
2.
Am J Clin Pathol ; 124(6): 930-6, 2005 Dec.
Article in English | MEDLINE | ID: mdl-16416743

ABSTRACT

Accurate diagnosis of monocytic neoplasms often is dependent on quantitating monoblasts, promonocytes, and monocytes. However, distinguishing these populations by morphologic assessment alone can be difficult and subject to significant intraobserver variability. We evaluated a 4-color flow cytometry technique using different anti-CD14 antibodies that recognize the MO2 and MY4 epitopes to identify monoblasts, promonocytes, and monocytes. Normal control specimens and 18 cases of monocytic neoplasia were evaluated and results correlated with morphologic findings. We found the MY4 epitope first appearing at the early promonocyte stage and the MO2 epitope appearing only on mature monocytes after the promonocyte stage. Expression of the MY4 and MO2 epitopes by neoplastic monocyte populations was found to usually parallel the normal monocyte differentiation patterns, although exceptions were noted. Our study suggests that 4-color flow cytometry may be an especially useful adjunct for morphologically difficult cases by providing an immunophenotypic measure of neoplastic monoblasts and promonocytes.


Subject(s)
Epitopes/immunology , Leukemia, Monocytic, Acute/diagnosis , Leukemia, Monocytic, Acute/immunology , Lipopolysaccharide Receptors/immunology , Monocytes/immunology , Flow Cytometry , Humans , Immunophenotyping , Lipopolysaccharide Receptors/metabolism
3.
Transfusion ; 44(12): 1769-73, 2004 Dec.
Article in English | MEDLINE | ID: mdl-15584993

ABSTRACT

BACKGROUND: Alterations in expression of adhesion molecules are important in the trafficking of hematopoietic progenitors and probably in the mobilization process. Relatively little and conflicting data are currently available on the differences in expression between good and poor mobilizing patients. STUDY DESIGN AND METHODS: In this study, the expression of eight adhesion molecules on the collected CD34+ cells from 36 patients undergoing mobilization was determined. RESULTS: Good mobilizing patients, defined as those who collected their target in one apheresis procedure, had significantly fewer cells that expressed CD11a (LFA-1) and CD54 (ICAM-1) and borderline fewer that expressed CD11c, CD49d (VLA-4), and CD49d (VLA-5). No differences were detected in CD11b (Mac-1), CD15s (sLe(x)), or CD62L (L-selectin). Linear regression analysis identified number of prior chemotherapy courses and expression of CD11a (LFA-1) as independent predictive factors for mobilization efficiency. Good and poor mobilizing patients had approximately the same number of total CD34+ cells collected and little difference in times to engraftment. CONCLUSIONS: CD11a (LFA-1) expression inversely correlates with mobilization efficiency. Elucidation of the mechanism(s) underlying these observations will require further study.


Subject(s)
Antigens, CD34/analysis , Cell Adhesion Molecules/analysis , Hematopoietic Stem Cell Mobilization , Adolescent , Adult , Female , Humans , Integrin alpha4beta1/analysis , Integrin alpha5beta1/analysis , Intercellular Adhesion Molecule-1/analysis , Lymphocyte Function-Associated Antigen-1/analysis , Male , Middle Aged
4.
Am J Clin Pathol ; 120(2): 228-35, 2003 Aug.
Article in English | MEDLINE | ID: mdl-12931553

ABSTRACT

Hairy cell leukemia (HCL) has been reported to sometimes express CD10. However, the reported frequencies have been quite variable and the significance of CD10 expression has not been addressed. Cases of HCL submitted to our flow cytometry service during a 2-year period were evaluated for CD10 expression. Information regarding demographics, clinical manifestations, tissue morphologic features, and response to treatment was reviewed. Of the 97 HCL cases identified, 10 expressed CD10. The level of CD10 staining was typically well above control levels and also could be detected easily by immunohistochemical analysis. All cases analyzed were negative for bcl-6. Our study suggests that approximately 10% of otherwise typical cases of HCL show aberrant CD10 expression. CD10+ HCL cases seem to be morphologically and clinically similar to CD10-HCL cases. Appreciating that HCL can express CD10 may be especially important when evaluating specimens with suboptimal morphologic features and/or limited immunophenotyping panels.


Subject(s)
Leukemia, Hairy Cell/metabolism , Neprilysin/metabolism , Adult , Aged , Aged, 80 and over , Biomarkers, Tumor/metabolism , Female , Flow Cytometry , Humans , Immunoenzyme Techniques , Immunophenotyping , Leukemia, Hairy Cell/immunology , Leukemia, Hairy Cell/pathology , Male , Middle Aged , Neprilysin/immunology
5.
Cytometry B Clin Cytom ; 52(1): 40-3, 2003 Mar.
Article in English | MEDLINE | ID: mdl-12599181

ABSTRACT

BACKGROUND: The issue of which specific antibodies need to be used when evaluating acute leukemias by flow cytometry is controversial. METHODS: Recent studies have suggested that antibodies against CD117 or c-kit are not essential for the assignment of blast lineage by flow cytometry, even though CD117 appears to be a very specific marker for myeloid lineage acute leukemias. We report a case of acute myeloid leukemia M2 subtype with an 8:21 translocation, where the leukemic blasts expressed CD117, CD19, and CD15 but did not show definitive expression of the myeloid markers CD13 or CD33. RESULTS AND CONCLUSIONS: This study highlights the importance of CD117 when evaluating acute leukemias by flow cytometry, which was necessary in this case to suggest that the blasts were phenotypically abnormal myeloblasts. In addition, this case presented an unusual acute myeloid leukemia phenotype that will likely be encountered by others and could be difficult to interpret.


Subject(s)
Flow Cytometry , Leukemia, Myeloid/immunology , Leukemia, Myeloid/pathology , Proto-Oncogene Proteins c-kit/immunology , Acute Disease , Antibodies , Biomarkers, Tumor/immunology , Cell Lineage/immunology , Humans , Immunophenotyping , Male , Middle Aged , Proto-Oncogene Proteins c-kit/analysis
6.
Transfusion ; 42(7): 904-11, 2002 Jul.
Article in English | MEDLINE | ID: mdl-12375664

ABSTRACT

BACKGROUND: An understanding of factors affecting CD34+ cell collection efficacy is essential to minimize donor toxicity and cost. STUDY DESIGN AND METHODS: Peripheral blood CD34+ cell (CD34) measurements were determined at various intervals before, during, and after automated cell collection (Cobe Spectra 6.0). The serial mean of multiple, intraprocedural CD34 levels was calculated for each procedure as an estimate of the mean, inlet-line CD34 level. RESULTS: The CD34+ concentration fell a mean of 30 percent in the first 30 to 70 minutes of collection. The degree of decline was inversely correlated with donor blood volume (BV), but was not due to hemodilution. The mean of the CD34 level before and after collection slightly overestimated the serial mean CD34 level. Cell yields, normalized for the CD34 level before collection, were higher from donors with larger BVs. CONCLUSIONS: The CD34 concentration rapidly decreased to a relative equilibrium level during the collection procedure. The degree of decrease in the CD34 level inversely correlated with the BV of the donor and was consistent with cell pooling in the collection set. The higher equilibrium CD34 levels in donors with larger BVs resulted in increased collection of CD34+ cells, and therefore, large-volume apheresis should be most efficient in these donors.


Subject(s)
Antigens, CD34/analysis , Hematopoietic Stem Cells/cytology , Hematopoietic Stem Cells/immunology , Leukapheresis/standards , Blood Donors , Blood Volume , Humans , Kinetics , Leukapheresis/methods
SELECTION OF CITATIONS
SEARCH DETAIL
...